NASDAQ:CUTR

Cutera Competitors

$27.50
-1.51 (-5.21 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$27.27
Now: $27.50
$29.26
50-Day Range
$26.02
MA: $30.99
$35.46
52-Week Range
$10.83
Now: $27.50
$38.80
Volume144,483 shs
Average Volume229,208 shs
Market Capitalization$489.03 million
P/E RatioN/A
Dividend YieldN/A
Beta1.6

Competitors

Cutera (NASDAQ:CUTR) Vs. BLFS, NTUS, AXGN, TMDX, VRAY, and ZYXI

Should you be buying CUTR stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Cutera, including BioLife Solutions (BLFS), Natus Medical (NTUS), AxoGen (AXGN), TransMedics Group (TMDX), ViewRay (VRAY), and Zynex (ZYXI).

BioLife Solutions (NASDAQ:BLFS) and Cutera (NASDAQ:CUTR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.

Institutional & Insider Ownership

67.7% of BioLife Solutions shares are owned by institutional investors. Comparatively, 87.8% of Cutera shares are owned by institutional investors. 22.3% of BioLife Solutions shares are owned by insiders. Comparatively, 2.3% of Cutera shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

BioLife Solutions has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Cutera has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for BioLife Solutions and Cutera, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioLife Solutions01902.90
Cutera01302.75

BioLife Solutions currently has a consensus target price of $46.6667, indicating a potential upside of 48.10%. Cutera has a consensus target price of $30.6667, indicating a potential upside of 11.52%. Given BioLife Solutions' stronger consensus rating and higher possible upside, research analysts clearly believe BioLife Solutions is more favorable than Cutera.

Profitability

This table compares BioLife Solutions and Cutera's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioLife Solutions12.67%0.53%0.43%
Cutera-18.83%-61.21%-25.31%

Valuation & Earnings

This table compares BioLife Solutions and Cutera's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLife Solutions$27.37 million38.45$-1,660,000.00$0.08393.88
Cutera$181.71 million2.69$-12,350,000.00($0.88)-31.25

BioLife Solutions has higher earnings, but lower revenue than Cutera. Cutera is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Summary

BioLife Solutions beats Cutera on 10 of the 14 factors compared between the two stocks.

Cutera (NASDAQ:CUTR) and Natus Medical (NASDAQ:NTUS) are both small-cap computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Institutional and Insider Ownership

87.8% of Cutera shares are held by institutional investors. Comparatively, 89.7% of Natus Medical shares are held by institutional investors. 2.3% of Cutera shares are held by insiders. Comparatively, 1.5% of Natus Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Cutera has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Natus Medical has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Cutera and Natus Medical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cutera01302.75
Natus Medical01002.00

Cutera presently has a consensus price target of $30.6667, indicating a potential upside of 11.52%. Given Cutera's stronger consensus rating and higher probable upside, research analysts plainly believe Cutera is more favorable than Natus Medical.

Profitability

This table compares Cutera and Natus Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cutera-18.83%-61.21%-25.31%
Natus Medical-4.33%3.87%2.50%

Earnings and Valuation

This table compares Cutera and Natus Medical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cutera$181.71 million2.69$-12,350,000.00($0.88)-31.25
Natus Medical$495.52 million1.84$-15,670,000.00$1.2421.76

Cutera has higher earnings, but lower revenue than Natus Medical. Cutera is trading at a lower price-to-earnings ratio than Natus Medical, indicating that it is currently the more affordable of the two stocks.

Summary

Cutera beats Natus Medical on 8 of the 14 factors compared between the two stocks.

Cutera (NASDAQ:CUTR) and AxoGen (NASDAQ:AXGN) are both small-cap computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Profitability

This table compares Cutera and AxoGen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cutera-18.83%-61.21%-25.31%
AxoGen-22.98%-19.83%-14.88%

Earnings and Valuation

This table compares Cutera and AxoGen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cutera$181.71 million2.69$-12,350,000.00($0.88)-31.25
AxoGen$106.71 million6.98$-29,140,000.00($0.68)-26.88

Cutera has higher revenue and earnings than AxoGen. Cutera is trading at a lower price-to-earnings ratio than AxoGen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and target prices for Cutera and AxoGen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cutera01302.75
AxoGen02302.60

Cutera presently has a consensus price target of $30.6667, indicating a potential upside of 11.52%. AxoGen has a consensus price target of $23.75, indicating a potential upside of 29.92%. Given AxoGen's higher probable upside, analysts plainly believe AxoGen is more favorable than Cutera.

Volatility and Risk

Cutera has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, AxoGen has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500.

Institutional and Insider Ownership

87.8% of Cutera shares are held by institutional investors. Comparatively, 78.4% of AxoGen shares are held by institutional investors. 2.3% of Cutera shares are held by insiders. Comparatively, 6.9% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Cutera beats AxoGen on 7 of the 13 factors compared between the two stocks.

TransMedics Group (NASDAQ:TMDX) and Cutera (NASDAQ:CUTR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Institutional & Insider Ownership

76.7% of TransMedics Group shares are held by institutional investors. Comparatively, 87.8% of Cutera shares are held by institutional investors. 13.1% of TransMedics Group shares are held by insiders. Comparatively, 2.3% of Cutera shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares TransMedics Group and Cutera's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransMedics Group$23.60 million29.04$-33,550,000.00($2.36)-10.61
Cutera$181.71 million2.69$-12,350,000.00($0.88)-31.25

Cutera has higher revenue and earnings than TransMedics Group. Cutera is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares TransMedics Group and Cutera's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TransMedics Group-131.35%-38.95%-24.10%
Cutera-18.83%-61.21%-25.31%

Analyst Ratings

This is a summary of recent ratings and recommmendations for TransMedics Group and Cutera, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TransMedics Group02302.60
Cutera01302.75

TransMedics Group presently has a consensus price target of $44.20, indicating a potential upside of 76.52%. Cutera has a consensus price target of $30.6667, indicating a potential upside of 11.52%. Given TransMedics Group's higher probable upside, equities analysts clearly believe TransMedics Group is more favorable than Cutera.

Risk & Volatility

TransMedics Group has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500. Comparatively, Cutera has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500.

Summary

Cutera beats TransMedics Group on 7 of the 13 factors compared between the two stocks.

ViewRay (NASDAQ:VRAY) and Cutera (NASDAQ:CUTR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations.

Profitability

This table compares ViewRay and Cutera's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ViewRay-166.74%-63.41%-36.34%
Cutera-18.83%-61.21%-25.31%

Institutional and Insider Ownership

83.0% of ViewRay shares are held by institutional investors. Comparatively, 87.8% of Cutera shares are held by institutional investors. 15.5% of ViewRay shares are held by insiders. Comparatively, 2.3% of Cutera shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for ViewRay and Cutera, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ViewRay11502.57
Cutera01302.75

ViewRay currently has a consensus price target of $4.50, indicating a potential upside of 14.21%. Cutera has a consensus price target of $30.6667, indicating a potential upside of 11.52%. Given ViewRay's higher probable upside, equities research analysts plainly believe ViewRay is more favorable than Cutera.

Volatility & Risk

ViewRay has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Cutera has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500.

Valuation & Earnings

This table compares ViewRay and Cutera's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ViewRay$87.78 million7.22$-120,200,000.00($1.18)-3.34
Cutera$181.71 million2.69$-12,350,000.00($0.88)-31.25

Cutera has higher revenue and earnings than ViewRay. Cutera is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

Summary

Cutera beats ViewRay on 9 of the 14 factors compared between the two stocks.

Cutera (NASDAQ:CUTR) and Zynex (NASDAQ:ZYXI) are both small-cap computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Profitability

This table compares Cutera and Zynex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cutera-18.83%-61.21%-25.31%
Zynex18.08%50.67%35.56%

Risk & Volatility

Cutera has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, Zynex has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Cutera and Zynex, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cutera01302.75
Zynex02202.50

Cutera currently has a consensus target price of $30.6667, indicating a potential upside of 11.52%. Zynex has a consensus target price of $21.6250, indicating a potential upside of 45.92%. Given Zynex's higher probable upside, analysts plainly believe Zynex is more favorable than Cutera.

Institutional and Insider Ownership

87.8% of Cutera shares are owned by institutional investors. Comparatively, 29.6% of Zynex shares are owned by institutional investors. 2.3% of Cutera shares are owned by company insiders. Comparatively, 50.5% of Zynex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Cutera and Zynex's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cutera$181.71 million2.69$-12,350,000.00($0.88)-31.25
Zynex$45.47 million11.36$9.49 million$0.2852.93

Zynex has lower revenue, but higher earnings than Cutera. Cutera is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Summary

Zynex beats Cutera on 9 of the 14 factors compared between the two stocks.


Cutera Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BioLife Solutions logo
BLFS
BioLife Solutions
2.1$31.51-3.8%$1.05 billion$27.37 million-43.16Insider Selling
Increase in Short Interest
NTUS
Natus Medical
1.1$26.98-4.0%$913.92 million$495.52 million-49.05
AxoGen logo
AXGN
AxoGen
1.7$18.28-2.6%$745.31 million$106.71 million-29.02News Coverage
TransMedics Group logo
TMDX
TransMedics Group
1.6$25.04-3.9%$685.35 million$23.60 million-17.89Increase in Short Interest
ViewRay logo
VRAY
ViewRay
1.5$3.94-5.8%$633.56 million$87.78 million-4.43News Coverage
Zynex logo
ZYXI
Zynex
1.8$14.82-4.7%$540.60 million$45.47 million44.91News Coverage
Edap Tms logo
EDAP
Edap Tms
1.3$8.33-2.2%$242.94 million$50.23 million-138.83Increase in Short Interest
Gap Down
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$7.34-4.9%$204.85 million$3.38 million-3.84Decrease in Short Interest
FONR
FONAR
1.1$17.62-1.6%$115.48 million$85.69 million16.62
IRIDEX logo
IRIX
IRIDEX
0.9$7.07-5.0%$109.73 million$43.45 million-12.85
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$3.43-3.8%$109.04 millionN/A0.00
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.20-4.1%$91.52 million$10,000.00-1.20Analyst Downgrade
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.10-7.3%$87.70 millionN/A-1.45Analyst Downgrade
Increase in Short Interest
electroCore logo
ECOR
electroCore
1.4$1.74-6.3%$84.35 million$2.39 million-2.20Gap Down
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.3$17.10-1.2%$39.52 million$1.50 million-0.98
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.03-5.4%$30.37 million$5.51 million-0.10Increase in Short Interest
News Coverage
Viveve Medical logo
VIVE
Viveve Medical
0.9$2.63-2.7%$26.48 million$6.57 million-0.01
Star Equity logo
STRR
Star Equity
0.1$2.76-3.6%$13.59 million$114.18 million-0.88
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.